| Popis: |
Approximately 75% of women with ovarian cancer are diagnosed at advanced stages (FIGO stage III/IV), with 15-23 months median global survival and 20% 5year survival. Angiogenesis plays an important role in tumour development and proliferation. Increased angiogenesis is associated with worse clinical outcome in ovarian cancer. Here we review the play of bevacizumab in the treatment of ovarian cancer and also other antiangiogenic drugs. In total, to date there are no promising results for most of the reviewed antiangiogenic agents, except those already known for bevacizumab, trebananib, pazopanib, cediranib and nintedanib. Ongoing re‐ search will shed more light on this fascinating tumour process and its control. |
